Praziquantel for the treatment of schistosomiasis during human pregnancy.
Friedman, Jennifer F;
Olveda, Remigio M;
Mirochnick, Mark H;
Bustinduy, Amaya L;
Elliott, Alison M;
(2017)
Praziquantel for the treatment of schistosomiasis during human pregnancy.
Bulletin of the World Health Organization, 96 (1).
pp. 59-65.
ISSN 0042-9686
DOI: https://doi.org/10.2471/BLT.17.198879
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
In 2014, an estimated 40 million women of reproductive age were infected with Schistosoma haematobium, S. japonicum and/or S. mansoni. In both 2003 and 2006, the World Health Organization (WHO) recommended that all schistosome-infected pregnant and breastfeeding women be offered treatment, with praziquantel, either individually or during treatment campaigns. In 2006, WHO also stated the need for randomized controlled trials to assess the safety and efficacy of such treatment. Some countries have yet to follow the recommendation on treatment and many programme managers and pregnant women in other countries remain reluctant to follow the recommended approach. Since 2006, two randomized controlled trials on the use of praziquantel during pregnancy have been conducted: one against S. mansoni in Uganda and the other against S. japonicum in the Philippines. In these trials, praziquantel treatment of pregnant women had no significant effect on birth weight, appeared safe and caused minimal side-effects that were similar to those seen in treated non-pregnant subjects. Having summarized the encouraging data, on efficacy, pharmacokinetics and safety, from these two trials and reviewed the safety data from non-interventional human studies, we recommend that all countries include pregnant women in praziquantel treatment campaigns. We identify the barriers to the treatment of pregnant women, in countries that already include such women in individual treatments and mass drug administration campaigns, and discuss ways to address these barriers.